GlassScriptPhysician profile
Joseph Mascaro
NPI 1841834710
$3,712.04
in general payments reported to CMS, 2019-2025
27 companies · $817 in 2025
The $817 reported for 2025 was more than what 81% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $564 · 2022: $805 · 2023: $839 · 2024: $688 · 2025: $817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,343.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $866.09 | 2021-2024 | Xarelto |
| Novo Nordisk INC | $596.79 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $419.44 | 2021-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $297.79 | 2021-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $287.91 | 2021-2025 | Farxiga, Lokelma, Wainua |
| Merck Sharp & Dohme LLC | $205.40 | 2021-2024 | Verquvo |
| Amgen INC. | $196.71 | 2024-2025 | Repatha, Repatha |
| Pfizer INC. | $147.95 | 2021-2024 | |
| Alnylam Pharmaceuticals INC. | $131.88 | 2024-2025 | Onpattro |
| Novartis Pharmaceuticals Corporation | $83.19 | 2022-2025 | |
| Janssen Biotech, INC. | $69.84 | 2021 | |
| Abbott Laboratories | $59.72 | 2022-2025 | Jot Dx |
| United Therapeutics Corporation | $48.57 | 2025 | Tyvaso |
| Atricure, INC. | $33.55 | 2023 | |
| Scpharmaceuticals INC. | $30.86 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $30.83 | 2024 | Arcalyst |
| Heartflow, INC. | $24.78 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $24.20 | 2023 | Inpefa |
| Glaxosmithkline, LLC. | $23.86 | 2025 | Arexvy, Shingrix |
| Edwards Lifesciences Corporation | $20.62 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Kiniksa Pharmaceuticals, LTD. | $19.36 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $19.04 | 2021 | |
| Acarix USA INC. | $16.78 | 2023 | Cadscor System |
| Arbor Pharmaceuticals, INC. | $16.31 | 2021 | |
| Genzyme Corporation | $13.94 | 2024 | |
| Daiichi Sankyo INC. | $13.73 | 2022 | |
| Abbvie INC. | $12.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Mascaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.